Literature DB >> 23568260

Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Sid P Kerkar1, Anthony J Leonardi, Nicolas van Panhuys, Ling Zhang, Zhiya Yu, Joseph G Crompton, Jenny H Pan, Douglas C Palmer, Richard A Morgan, Steven A Rosenberg, Nicholas P Restifo.   

Abstract

Engineering CD8⁺ T cells to deliver interleukin 12 (IL-12) to the tumor site can lead to striking improvements in the ability of adoptively transferred T cells to induce the regression of established murine cancers. We have recently shown that IL-12 triggers an acute inflammatory environment that reverses dysfunctional antigen presentation by myeloid-derived cells within tumors and leads to an increase in the infiltration of adoptively transferred antigen-specific CD8⁺ T cells. Here, we find that local delivery of IL-12 increased the expression of Fas within tumor-infiltrating macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSC), and that these changes were abrogated in mice deficient in IL-12-receptor signaling. Importantly, upregulation of Fas in host mice played a critical role in the proliferation and antitumor activity of adoptively transferred IL-12-modified CD8⁺ T cells. We also observed higher percentages of myeloid-derived cell populations within tumors in Fas-deficient mice, indicating that tumor stromal destruction was dependent on the Fas death receptor. Taken together, these results describe the likely requirement for costimulatory reverse signaling through Fasl on T cells that successfully infiltrate tumors, a mechanism triggered by the induction of Fas expression on myeloid-derived cells by IL-12 and the subsequent collapse of the tumor stroma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568260      PMCID: PMC3702103          DOI: 10.1038/mt.2013.58

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

Review 1.  Cellular constituents of immune escape within the tumor microenvironment.

Authors:  Sid P Kerkar; Nicholas P Restifo
Journal:  Cancer Res       Date:  2012-06-21       Impact factor: 12.701

2.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

Review 3.  Interleukin-12 in anti-tumor immunity and immunotherapy.

Authors:  Mario P Colombo; Giorgio Trinchieri
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

4.  IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.

Authors:  Markus Chmielewski; Caroline Kopecky; Andreas A Hombach; Hinrich Abken
Journal:  Cancer Res       Date:  2011-07-08       Impact factor: 12.701

5.  Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.

Authors:  J M Wigginton; J W Park; M E Gruys; H A Young; C L Jorcyk; T C Back; M J Brunda; R M Strieter; J Ward; J E Green; R H Wiltrout
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

6.  T-cell therapy at the threshold.

Authors:  Carl June; Steven A Rosenberg; Michel Sadelain; Jeffrey S Weber
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

7.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

Review 8.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

9.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

10.  A human memory T cell subset with stem cell-like properties.

Authors:  Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440

View more
  29 in total

1.  Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.

Authors:  Jacob S Bowers; Michelle H Nelson; Sreenath Kundimi; Stefanie R Bailey; Logan W Huff; Kristina M Schwartz; David J Cole; Mark P Rubinstein; Chrystal M Paulos
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

2.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

Review 3.  CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Authors:  Hollie J Pegram; Eric L Smith; Sarwish Rafiq; Renier J Brentjens
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 4.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

Review 5.  Genetically modified T-cell therapy for osteosarcoma.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 6.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Authors:  Grammatiki Fotaki; Chuan Jin; Mohanraj Ramachandran; Iliana Kyriaki Kerzeli; Alex Karlsson-Parra; Di Yu; Magnus Essand
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 9.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 10.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.